Skip to content

Clinical trials

Small Cell Lung Carcinoma trials in the United States with no applicable phase

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Small Cell Lung Carcinoma Phase: Not applicable Country / region: United States Clear all

35 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20001
20011
20021
20031
20041
20054
20064
20081
20091
20101
20111
20132
20141
20151
20182
20191
20204
20221
20232
20251
20261

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed20
Recruiting5
Terminated5
Active, not recruiting4
Unknown status1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Massachusetts General Hospital3
M.D. Anderson Cancer Center2
Memorial Sloan Kettering Cancer Center2
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins2
Stanford University2
Barbara Ann Karmanos Cancer Institute1
Beth Israel Deaconess Medical Center1
Brigham and Women's Hospital1
Butler Hospital1
City of Hope Medical Center1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Small Cell Lung Carcinoma35
Carcinoma, Non-Small-Cell Lung29
Lung Neoplasms21
Esophageal Neoplasms7
Breast Neoplasms6
Carcinoma, Renal Cell5
Pancreatic Neoplasms5
Prostatic Neoplasms5
Stomach Neoplasms5
Carcinoma, Ovarian Epithelial4

Trials

Showing 1 to 25 of 35. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.